generic glp-1 Liraglutide (Victoza) Becomes First Generic Receptor Agonist Liraglutide Injection Marks Debut as

Tirzepatide was approved in 2022 as Mounjaro for diabetes, and in 2024 as Zepbound for obesity, with exclusivity running until May 2027

Made in the USA in an FDA-registered, GMP-certified facility and 3rd-party tested for quality

FORTIFY GI TRACT*

GLP-1 Injections: like Ozempic and Wegovy

The aim of the present review is to examine the cellular processes underlying the actions of these new, highly significant classes of peptide receptor agonists

RYGB produces higher early postprandial increases in GLP-1 and glucose than OAGB, demonstrating that procedural differences can influence gut hormone and glucose responses.